Cure My Disease

Don't miss your cure!

 Log in / Sign up

Home injection trial for myasthenia gravis shows promise

NCT ID NCT05681715

Completed Symptom relief Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether 62 people with generalized myasthenia gravis could learn to self-administer the drug rozanolixizumab at home using a syringe driver or manual push. Participants were trained and then assessed on their ability to correctly give themselves the infusion. The goal was to see if home self-administration is feasible and safe, potentially offering more convenience for patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
rozanolixizumab
What this could lead to
If successful, this could allow people with generalized myasthenia gravis to conveniently administer their medication at home instead of at a clinic.
What could go wrong
This is a small, completed Phase 3 study focused on self-administration ability, not on whether the drug works better than other options. Some participants may still have difficulty or experience side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENERALIZED MYASTHENIA GRAVIS

Contacts and locations

Locations

  • Mg0020 20068

    Chiba, Japan

  • Mg0020 20076

    Shinjuku-ku, Japan

  • Mg0020 20077

    Sendai, Japan

  • Mg0020 20078

    Hanamaki-shi, Japan

  • Mg0020 20161

    Tbilisi, Georgia

  • Mg0020 20165

    Tbilisi, Georgia

  • Mg0020 20305

    Tbilisi, Georgia

  • Mg0020 40140

    Göttingen, Germany

  • Mg0020 40144

    Milan, Italy

  • Mg0020 40146

    Pavia, Italy

  • Mg0020 40150

    Roma, Italy

  • Mg0020 40153

    Poznan, Poland

  • Mg0020 40155

    Gdansk, Poland

  • Mg0020 40160

    Barcelona, Spain

  • Mg0020 40163

    Oxford, United Kingdom

  • Mg0020 40168

    Nottingham, United Kingdom

  • Mg0020 40177

    Münster, Germany

  • Mg0020 40267

    Barcelona, Spain

  • Mg0020 40308

    San Sebastián de los Reyes, Spain

  • Mg0020 40727

    Lodz, Poland

  • Mg0020 40729

    Niš, Serbia

  • Mg0020 50069

    Toronto, Canada

  • Mg0020 50090

    Winston-Salem, North Carolina, 27157, United States

  • Mg0020 50092

    Orange, California, 92868, United States

  • Mg0020 50099

    San Francisco, California, 94143, United States

  • Mg0020 50560

    Edmonton, Canada

  • Mg0020 50561

    Lexington, Kentucky, 40536-0284, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.